1. Scrip
  2. >>Business
  3. >>Deals

Pharma Products Face Uncertain Future In Boston Scientific's 'Logical' £3.3bn Bid For UK's BTG

 
• By Sten Stovall

Boston Scientific CEO says US group has been tracking UK-based BTG "for more than two years" and that interventional medicine is a key attraction.

IT transaction or merger between companies
BTG Board Has Recommended Boston Scientific's 840p/share cash offer • Source: Shutterstock

Boston Scientific Corp.'s recommended cash offer for BTG PLC is being applauded by analysts as logical - despite a full price tag - for its complementary fit and potential for the US group's international infrastructure to grow the diversified British group's sales outside the US, where it currently generates some 90% of its total revenues. However, the future of BTG's specialty medicines is not yet clear.

The US medical devices manufacturer on Nov. 20 announced it had made a recommended 840p cash per share offer for the diversified UK-based group, implying a valuation of £3.3bn ($4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.